TDLN-sparing RT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC

  • STATUS
    Recruiting
  • End date
    Feb 12, 2031
  • participants needed
    452
  • sponsor
    Fudan University
Send
Updated on 12 May 2025
See if I qualify

Summary

The goal of this clinical trial is to learn if tumor draining lymph nodes-sparing radiotherapy (TDLN-sparing RT) followed by immunotherapy as maintenance therapy works to treat locally advanced esophageal squamous cell cancer in adults.

Details
Condition Esophageal Carcinoma, Radiotherapy, Immunotherapy
Age 18years or above
Clinical Study IdentifierNCT06964568
SponsorFudan University
Last Modified on12 May 2025

Eligibility

 Yes No Not Sure

Inclusion Criteria

Written informed consent
Aged 18 years or above
Histologically confirmed esophageal squamous cell carcinoma
Clinical stages T3-4N0M0 or TxN+M0 or TxNxM1 (Only for supraclavicular lymph nodes) based on the 8th UICC-TNM classification
\. Eastern Cooperative Oncology Group(ECOG) performance status: 0-1 8. Life
expectancy ≥3 months 9. Adequate organ functions Absolute neutrophil counts
(ANC) ≥1.5×109⁄L; Hemoglobin (Hb) ≥9g⁄dl; Platelet (Plt) ≥100×109⁄L; Total
bilirubin ≤1.5 upper limit of normal (ULN); Aspartate transaminase (AST) ≤2.5
ULN; Alanine aminotransferase (ALT) ≤2.5 ULN; Creatinine ≤1.5 ULN

Exclusion Criteria

Esophageal perforation or hematemesis
Any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism and hypothyroidism (effective hormone replacement therapy excepted)) and immunosuppressive agents or systemic hormonal therapy indicated within 28 days (for adverse events of chemoradiotherapy excepted)
Previously received or receiving PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1
Allergic to any of the ingredients in PD-1 inhibitors for injection
Uncontrolled heart diseases or clinical symptoms, such as: (1) New York Heart Association(NYHA) class II or higher heart failure; (2) unstable angina; (3) myocardial infarction within 1 year; (4)clinically significant arrhythmia requiring clinical intervention
Congenital or acquired immunodeficiency (such as HIV infection); active hepatitis B (HBV-DNA≥104 copy number/ml) or hepatitis C (positive hepatitis C antibody, and HCV-RNA is higher than the detection limit of the analytical method); active tuberculosis
Active infection or unexplained fever >38.5 °C within 2 weeks before randomization (fever due to tumor excepted, according to investigator)
Patients with fertility reluctant to take contraceptive measures during the
trial, or female patients pregnant or breastfeeding
According to the investigator, other factors that may cause termination of the study. ie, other serious diseases (including mental illness) require combined treatment, family or social factors, which may affect the safety or the collection of trial data
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.56
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.57
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.58
Sign up59

Send a message24

Enter your contact details to connect with study team25

Investigator Avatar

Primary Contact26

First name*27
Last name*30
Email*33
Phone number*37
Preferred way of contact label
Race
Ethnicity
Other language43

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.